Paul Maciocia

801 total citations
23 papers, 504 citations indexed

About

Paul Maciocia is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Paul Maciocia has authored 23 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Dermatology. Recurrent topics in Paul Maciocia's work include CAR-T cell therapy research (16 papers), Cutaneous lymphoproliferative disorders research (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Paul Maciocia is often cited by papers focused on CAR-T cell therapy research (16 papers), Cutaneous lymphoproliferative disorders research (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Paul Maciocia collaborates with scholars based in United Kingdom, Italy and Belgium. Paul Maciocia's co-authors include Martin Pulé, Shimobi Onuoha, Brian Philip, Patrycja Wawrzyniecka, Giuseppe Gritti, David C. Linch, Teresa Marafioti, Joan Somja, David K. Cole and Andrew K. Sewell and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paul Maciocia

22 papers receiving 494 citations

Peers

Countries citing papers authored by Paul Maciocia

Since Specialization

Citations

This map shows the geographic impact of Paul Maciocia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Maciocia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Maciocia more than expected).

Fields of papers citing papers by Paul Maciocia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Maciocia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Maciocia. The network helps show where Paul Maciocia may publish in the future.

Co-authorship network of co-authors of Paul Maciocia

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Maciocia. A scholar is included among the top collaborators of Paul Maciocia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Maciocia. Paul Maciocia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry 2024 ·Blood Cancer Journal ·Pedro Horna, (unknown), Mathieu Ferrari, (unknown), (unknown), (unknown), (unknown), Gregory E. Otteson, Jansen N. Seheult, Janosch Ortmann, Min Shi, Paul Maciocia, (unknown), Martin Pulé, Horatiu Olteanu	13
2	Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy 2024 ·SHILAP Revista de lepidopterología ·Orla McCourt, Paul Maciocia, Claire Roddie, (unknown), (unknown), (unknown), (unknown), Maise Al Bakir, Maeve O’Reilly	1
3	CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? 2024 ·Blood Advances ·(unknown), Bridget S. Wade, Paul Maciocia	4
4	A Novel Protein-Based Approach to Generate Allogeneic CAR-T Cells with Simultaneous TCR and MHC Class 1 Downregulation 2022 ·Blood ·(unknown), Patrycja Wawrzyniecka, (unknown), (unknown), (unknown), Martin Pulé, Paul Maciocia	2
5	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia 2022 ·Blood ·Paul Maciocia, Patrycja Wawrzyniecka, (unknown), (unknown), (unknown), (unknown), (unknown), David O’Connor, Theresa E. León, (unknown), Rachael Pocock, Sunniyat Rahman, Giuseppe Gritti, Diana C. Yánez, Susan R. Ross, Tessa Crompton, Owen Williams, Lydia Lee, Martin Pulé, Marc R. Mansour	44
6	Chimeric antigen receptor T cells for gamma–delta T cell malignancies 2021 ·Leukemia ·Patrycja Wawrzyniecka, (unknown), Giuseppe Gritti, Martin Pulé, Paul Maciocia	9
7	Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL) 2021 ·Blood ·(unknown), (unknown), Francesco Nannini, Patrycja Wawrzyniecka, (unknown), (unknown), Mathieu Ferrari, Teresa Marafioti, Shimobi Onuoha, Asim Khwaja, Paul Maciocia, Martin Pulé	7
8	Anti-CCR9 CAR-T Cells for T Acute Lymphoblastic Leukemia 2021 ·Blood ·Paul Maciocia, Patrycja Wawrzyniecka, (unknown), (unknown), David O’Connor, Theresa E. León, (unknown), (unknown), Martin Pulé, Marc R. Mansour	2
9	Analysis of T-Cell Receptor Beta-Constant Region Expression for Rapid Assessment of T-Cell Clonality 2018 ·Blood ·Paul Maciocia, (unknown), Shimobi Onuoha, Patrycja Wawrzyniecka, Giuseppe Gritti, Manuela Tosi, (unknown), Martin Pulé, Teresa Marafioti	1
10	Chimeric Antigen Receptor T-Cells for the Treatment of Gamma-Delta T-Cell Malignancies 2018 ·Blood ·Paul Maciocia, Patrycja Wawrzyniecka, (unknown), Martin Pulé	1
11	A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1 2018 ·British Journal of Haematology ·Selina J Chavda, Paul Maciocia, (unknown), Nicholas Counsell, Jaimal Kothari, A G Bird, (unknown), (unknown), (unknown), Sally Moore, (unknown), Ali Rismani, Shirley D’Sa, Neil Rabin, Rakesh Popat, Kwee Yong	2
12	A Protein-Based Method to Develop Allogeneic Chimeric Antigen Receptor T-Cells 2018 ·Blood ·Paul Maciocia, Patrycja Wawrzyniecka, (unknown), Martin Pulé	4
13	Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies 2017 ·Nature Medicine ·Paul Maciocia, Patrycja Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U. Akarca, Shimobi Onuoha, Mateusz Legut, David K. Cole, Andrew K. Sewell, Giuseppe Gritti, Joan Somja, Miguel Á. Piris, Karl S. Peggs, David C. Linch, Teresa Marafioti, Martin Pulé	192
14	An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma 2017 ·Blood ·Lydia Lee, Benjamin Draper, (unknown), Brian Philip, (unknown), (unknown), Shimobi Onuoha, Simon Thomas, Vania Baldan, Reyisa Bughda, Paul Maciocia, (unknown), (unknown), Dominic Patel, Manuel Rodriguez‐Justo, (unknown), Kwee Yong, Martin Pulé	134
15	TARGETING THE T‐CELL RECEPTOR Β‐CONSTANT DOMAIN FOR IMMUNOTHERAPY OF T‐CELL MALIGNANCIES 2017 ·Hematological Oncology ·Paul Maciocia, Patrycja Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U. Akarca, (unknown), Duncan Cole, Andrew K. Sewell, Karl S. Peggs, David C. Linch, Teresa Marafioti, Martin Pulé	2
16	Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience 2016 ·Blood ·(unknown), Andrew Melville, Paul Maciocia, (unknown), Faye Sharpley, Karthik Ramasamy, Matthew Streetly, Matthew Jenner, (unknown), Stephen Schey, Rakesh Popat, Shirley D’Sa, Ali Rismani, Kwee Yong, Neil Rabin	1
17	Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies 2016 ·Blood ·Paul Maciocia, Patrycja Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U. Akarca, Shimobi Onuoha, David K. Cole, Andrew K. Sewell, Karl S. Peggs, David C. Linch, Teresa Marafioti, Martin Pulé	0
18	Treatment of diffuse large B‐cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS‐penetrating R‐IDARAM chemotherapy 2015 ·British Journal of Haematology ·Paul Maciocia, Mohsin Badat, (unknown), Shirley D’Sa, Rahul Joshi, Jonathan Lambert, (unknown), Martin Pulé, David C. Linch, Kirit M. Ardeshna	20
19	Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk 2013 ·Blood ·Paul Maciocia, Nicholas Counsell, A G Bird, (unknown), Sally Moore, Neil Rabin, Shirley D’Sa, Manuel Rodriguez‐Justo, Kwee Yong	1
20	Pain assessment in the paediatric Emergency Department: whose view counts? 2003 ·European Journal of Emergency Medicine ·Paul Maciocia, (unknown), Ahsan R. Akram, (unknown), (unknown), Alison Kemp, (unknown), Laura Smith, T F Beattie	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact